Hye In Woo1, Jisook Park2, Shinn-Won Lim3, Doh Kwan Kim4, Soo-Youn Lee5,6. 1. Department of Laboratory Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea. 2. Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 3. SAIHST, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea. 4. Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. paulkim@skku.edu. 5. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. suddenbz@skku.edu. 6. Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. suddenbz@skku.edu.
Abstract
BACKGROUND: Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expression levels after antidepressant treatment and investigate differences in protein expression between MDD patients and healthy individuals. METHODS: A total of 111 proteins obtained from literature review were subjected to multiple reaction monitoring (MRM)-based protein quantitation. Finally, seven proteins were quantified for plasma specimens of 10 healthy controls and 78 MDD patients (those at baseline and at 6 weeks after antidepressant treatment of either selective serotonin reuptake inhibitors (SSRIs) or mirtazapine). RESULTS: Among 78 MDD patients, 35 patients were treated with SSRIs and 43 patients were treated with mirtazapine. Nineteen (54.3%) and 16 (37.2%) patients responded to SSRIs and mirtazapine, respectively. Comparing MDD patients with healthy individuals, alteration of transthyretin was observed in MDD (P = 0.026). A few differences were observed in protein levels related to SSRIs treatment, although they were not statistically significant. Plasma thyroxine-binding globulin (TBG) was different between before and after mirtazapine treatment only in responders (P = 0.007). CONCLUSIONS: In proteomic analysis of plasma specimens from MDD patients, transthyretin and TBG levels were altered in MDD and changed after antidepressant treatment.
BACKGROUND: Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expression levels after antidepressant treatment and investigate differences in protein expression between MDDpatients and healthy individuals. METHODS: A total of 111 proteins obtained from literature review were subjected to multiple reaction monitoring (MRM)-based protein quantitation. Finally, seven proteins were quantified for plasma specimens of 10 healthy controls and 78 MDDpatients (those at baseline and at 6 weeks after antidepressant treatment of either selective serotonin reuptake inhibitors (SSRIs) or mirtazapine). RESULTS: Among 78 MDDpatients, 35 patients were treated with SSRIs and 43 patients were treated with mirtazapine. Nineteen (54.3%) and 16 (37.2%) patients responded to SSRIs and mirtazapine, respectively. Comparing MDDpatients with healthy individuals, alteration of transthyretin was observed in MDD (P = 0.026). A few differences were observed in protein levels related to SSRIs treatment, although they were not statistically significant. Plasma thyroxine-binding globulin (TBG) was different between before and after mirtazapine treatment only in responders (P = 0.007). CONCLUSIONS: In proteomic analysis of plasma specimens from MDDpatients, transthyretin and TBG levels were altered in MDD and changed after antidepressant treatment.
Authors: Claudia Ditzen; Ning Tang; Archana M Jastorff; Larysa Teplytska; Alexander Yassouridis; Giuseppina Maccarrone; Manfred Uhr; Thomas Bronisch; Christine A Miller; Florian Holsboer; Christoph W Turck Journal: Neuropsychopharmacology Date: 2011-12-14 Impact factor: 7.853
Authors: Gerald Gartlehner; Richard A Hansen; Laura C Morgan; Kylie Thaler; Linda Lux; Megan Van Noord; Ursula Mager; Patricia Thieda; Bradley N Gaynes; Tania Wilkins; Michaela Strobelberger; Stacey Lloyd; Ursula Reichenpfader; Kathleen N Lohr Journal: Ann Intern Med Date: 2011-12-06 Impact factor: 25.391
Authors: Latha Velayudhan; Richard Killick; Abdul Hye; Anna Kinsey; Andreas Güntert; Steven Lynham; Malcolm Ward; Rufina Leung; Anbarasu Lourdusamy; Alvina W M To; John Powell; Simon Lovestone Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Steven Moylan; Michael Berk; Olivia M Dean; Yuval Samuni; Lana J Williams; Adrienne O'Neil; Amie C Hayley; Julie A Pasco; George Anderson; Felice N Jacka; Michael Maes Journal: Neurosci Biobehav Rev Date: 2014-05-21 Impact factor: 8.989
Authors: Regina Taurines; Edward Dudley; Julia Grassl; Andreas Warnke; Manfred Gerlach; Andrew N Coogan; Johannes Thome Journal: J Psychopharmacol Date: 2010-02-08 Impact factor: 4.153
Authors: M Bot; M K Chan; R Jansen; F Lamers; N Vogelzangs; J Steiner; F M Leweke; M Rothermundt; J Cooper; S Bahn; B W J H Penninx Journal: Transl Psychiatry Date: 2015-07-14 Impact factor: 6.222
Authors: D Martins-de-Souza; P C Guest; L W Harris; N Vanattou-Saifoudine; M J Webster; H Rahmoune; S Bahn Journal: Transl Psychiatry Date: 2012-03-13 Impact factor: 6.222